Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma

Ferdinando C M Cananzi, Satvinder Mudan, Mary Dunne, Nneka Belonwu, Angus G. Dalgleish

Research output: Contribution to journalArticle

Abstract

Background: The long-term prognosis of patients with stage IV aJcc melanoma is extremely poor. We have previously published short-term clinical outcome and immunological responses to a heat killed Mycobacterium vaccae-based vaccine. Results: In this study we report on a better than expected long-term survival (3-y Dss 29·6%, 5-y, and 7-y Dss both 23·9%) relative to historical controls in the patients who received the vaccine in these trials, published in 1999 and 2003. although the complete or partial response was only 10%, it was the remarkable response to other interventions upon relapse, such as surgery and radiotherapy followed by stable disease that was previously unexpected. Methods: We reviewed the outcome of 72 patients who were treated with M. vaccae for metastatic melanoma between January 1996 and July 2004. Conclusion: Given this remarkable outcome in stage IV metastatic melanoma and its lack of toxicity we propose that this would make a promising candidate for randomized trials for stage III fully resected melanoma.

Original languageEnglish
Pages (from-to)2427-2433
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume9
Issue number11
DOIs
Publication statusPublished - 2013

Keywords

  • Long-term survival
  • Mycobacterial vaccine
  • Stage IV melanoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma'. Together they form a unique fingerprint.

  • Cite this